Status:
UNKNOWN
Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer
Lead Sponsor:
Peking University
Conditions:
Colorectal Cancer
Eligibility:
All Genders
Brief Summary
This is an observational, ambispective cohort study. The aim is to compare the efficacy and safety of regorafenib versus fruquintinib conducted in China. About 268 eligible metastatic colorectal cance...
Eligibility Criteria
Inclusion
- signed and dated informed consent.
- Diagnosis of histologically confirmed colorectal cancer, stage IV.
- after second-line therapy.
- gastrointestinal physician prescribed to receive regorafenib or fruquintinib according the patients' condition.
Exclusion
- received regorafenib or fruquintinib before third-line therapy.
- the clinicopathological characteristics and previous therapy were unknown.
- regorafenib or fruquintinib treatment is less than one cycle in the historical cohort.
Key Trial Info
Start Date :
May 25 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2022
Estimated Enrollment :
268 Patients enrolled
Trial Details
Trial ID
NCT04431791
Start Date
May 25 2020
End Date
February 1 2022
Last Update
June 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142